Trends in atrial fibrillation ablation: have we maximized the current paradigms?

Por Winkle, Roger A., Mead, R. Hardwin, Engel, Gregory, Kong, Melissa H., Patrawala, Rob A.
Publicado em 2012

Physician-controlled costs: the choice of equipment used for atrial fibrillation ablation

Por Winkle, Roger A., Mead, R. Hardwin, Engel, Gregory, Kong, Melissa H., Patrawala, Rob A.
Publicado em 2013

Discontinuing anticoagulation following successful atrial fibrillation ablation in patients with prior strokes

Por Winkle, Roger A., Mead, R. Hardwin, Engel, Gregory, Kong, Melissa H., Patrawala, Rob A.
Publicado em 2013

Comparison of CHADS(2) and CHA(2)DS(2)-VAS(C) anticoagulation recommendations: evaluation in a cohort of atrial fibrillation ablation patients

Por Winkle, Roger A., Mead, R. Hardwin, Engel, Gregory, Kong, Melissa H., Patrawala, Rob A.
Publicado em 2014

Prior antiarrhythmic drug use and the outcome of atrial fibrillation ablation

Por Winkle, Roger A., Mead, R. Hardwin, Engel, Gregory, Kong, Melissa H., Patrawala, Rob A.
Publicado em 2012

Peri-procedural interrupted oral anticoagulation for atrial fibrillation ablation: comparison of aspirin, warfarin, dabigatran, and rivaroxaban

Por Winkle, Roger A., Mead, R. Hardwin, Engel, Gregory, Kong, Melissa H., Patrawala, Rob A.
Publicado em 2014

Ablation of atypical atrial flutters using ultra high density-activation sequence mapping

Por Winkle, Roger A., Moskovitz, Ryan, Mead, R. Hardwin, Engel, Gregory, Kong, Melissa H., Fleming, William, Patrawala, Rob A.
Publicado no J Interv Card Electrophysiol (2016)